EBAC

Unit Split

European Biotech Acquisition Corp.

Raised
$127M
CIK
1841258
Focus
Life Sciences, Biotech
External link: SEC Filings

SPAC Team

Leadership

Eduardo Bravo Fernandez de Araoz: Eduardo has served as our Chief Executive Officer since our inception. From July 2020 to December 2020, Mr. Bravo was Interim Chief Executive Officer of OncoDNA, a cancer theranostic company. From July 2018 to February 2020, Mr. Bravo served Chief Executive Officer of Nordic Nanovector, a radiopharmaceutical company. Prior to joining Nordic Nanovector, Mr. Bravo was CEO of TiGenix, a cell therapy company from 2011 until June 2018. Mr. Bravo has a MSc in Business Administration from CUNEF (Madrid, Spain) (1988) and a MBA from INSEAD (1991). We believe that Mr. Bravo’s experience as an executive at leading biotechnology businesses make him well qualified to serve on our management team.

Koen Sintnicolaas has served as our Chief Financial Officer since our inception. From July 2016 to December 2020, Mr. Sintnicolaas was Business Controller of LSP, an affiliate of our sponsor and one of Europe’s largest and most experienced healthcare investment firms. From June 2013 to June 2016, Mr. Sintnicolaas served as Business Controller of Fetim Group, an international trading company. Mr. Sintnicolaas has a MSc in Financial Economics from the Erasmus University in Rotterdam and a post-graduate Business Analytics & Data Science degree from the Vrije Universiteit in Amsterdam. We believe that Mr. Sintnicolaas’ experience as a business controller at leading investment and international trading firms make him well qualified to serve on our management team.

Martijn Kleijwegt has been a member and the Chairman of our board of directors since our inception. Mr. Keijwegt founded LSP in 1998 and is currently a managing partner and co-owner of LSP. Mr. Kleijwegt brings over 30 years of hands-on finance and investment experience to EBAC. Mr. Kleijwegt currently serves on the boards of Vico Therapeutics, A-M Pharma, Arvelle Therapeutics, Eloxx Pharmaceuticals, Orphazyme, Oxthera, Pharvaris and Kiadis Pharma. Mr. Kleijwegt has a master’s degree in Economics from Amsterdam University, the Netherlads (1983). We believe that Mr. Kleijwegt’s experience in healthcare investments make him well qualified to serve as a director.

Mark Wegter has been a member of our board of directors since our inception. Mark joined LSP in 1998 and is a managing partner and co-owner of the firm. For the first ten years at LSP, Mark was actively involved in raising and managing LSP’s private equity funds, taking co-responsibility for the entire investment process, from deal sourcing to actively supporting the growth and exit of a number of LSP’s portfolio companies, as non-executive director and LSP investor representative. This included both private and public companies in countries such as the Netherlands, Belgium, Germany, the UK and Switzerland. As of early 2008, Mark started LSP’s public equity investment franchise, building it to become a second business line next to LSP’s existing private equity franchise. Since, Mark and his team have generated returns in excess of +1100% over the period 2008 – 2020, or +22% per annum. Such by investing in a highly concentrated portfolio of small- and mid-cap listed biotech companies active across therapeutic areas and at varying stage of development. Prior to joining LSP, Mark worked as a Senior Analyst at ING Corporate and Investment Banking. Mark brings 25 years of hands-on finance and investment experience to EBAC. Mark currently serves on the board of Kiadis Pharma, a Dutch biotech company listed on Euronext and active in the immune-oncology space (treatments for blood and solid cancers). Mark has a master’s degree in Business Economics from the Erasmus University of Rotterdam, Netherlands (1995). We believe Mr. Wegter’s experience in healthcare investments make him well qualified to serve as a director.